Source - RNS
RNS Number : 8030A
ConvaTec Group PLC
31 May 2019

ConvaTec Group Plc ("the Company") - Total Voting Rights

Reading, United Kingdom (31 May 2019)

The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. On 31 May 2019, the Company's issued capital with voting rights consists of 1,977,354,009 ordinary shares of 10p each.  The Company does not hold any shares in Treasury at the date of this disclosure.

The above figure (1,977,354,009) can be used by shareholders as the denominator for the calculations by which to determine if they are required to notify their interest in, or a change to, their interest in the Company under the UK Financial Conduct Authority's Disclosure and Transparency Rules. 



Bobby Leach, VP Group Corporate Affairs, ConvaTec                    +44 (0)7770 842226

Alastair Elwen, Finsbury                                                                    +44 (0)207 2513801

Analysts and Investors

John Crosse, VP Investor Relations, ConvaTec                                 +44 (0)7500 141435

Mark Reynolds, Director Investor Relations, ConvaTec                    +44 (0)7551 036625

[email protected]

ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92

About ConvaTec

ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices. ConvaTec's products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit where a copy of this announcement can also be found.



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit